In the FUSCC cohort, we found PIK3CA mutations were like to enriched in the metastatic HR‐HER2+ tumours which were exposed with long‐term trastuzumab‐based treatment via the analysis of variant allele fraction (VAF) (p = .0078, Figure 2A). The gene discussed is ERBB2; the disease is neoplasm.